These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25970122)

  • 1. [New Drugs for the Treatment of Multidrug-resistant Tuberculosis (MDR-TB)].
    Schaberg T; Otto-Knapp R; Bauer T
    Pneumologie; 2015 May; 69(5):282-6. PubMed ID: 25970122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New drugs for treatment of tuberculosis].
    Schaberg T
    Internist (Berl); 2016 Feb; 57(2):136-41. PubMed ID: 26787496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ▼Bedaquiline for multidrug-resistant tuberculosis.
    Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
    Szumowski JD; Lynch JB
    Drug Des Devel Ther; 2015; 9():677-82. PubMed ID: 25678771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    Gotham D; Fortunak J; Pozniak A; Khoo S; Cooke G; Nytko FE; Hill A
    J Antimicrob Chemother; 2017 Apr; 72(4):1243-1252. PubMed ID: 28073970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis.
    Milstein M; Brzezinski A; Varaine F; Mitnick CD
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):18-23. PubMed ID: 28240568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.
    Stancil SL; Mirzayev F; Abdel-Rahman SM
    Drug Des Devel Ther; 2021; 15():2815-2830. PubMed ID: 34234413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Annual progress of chemotherapy of multidrug/rifampicin-resistant tuberculosis in 2022].
    Yu JJ; Tang SJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Jan; 46(1):62-66. PubMed ID: 36617931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. News on therapeutic management of MDR-tuberculosis: a literature review.
    Barthod L; Lopez JG; Curti C; Bornet C; Roche M; Montana M; Vanelle P
    J Chemother; 2018 Feb; 30(1):1-15. PubMed ID: 28651480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
    Kakkar AK; Dahiya N
    Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?
    Cox V; Furin J
    Int J Tuberc Lung Dis; 2017 Dec; 21(12):1211-1213. PubMed ID: 29297439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clofazimine in the treatment of multidrug-resistant tuberculosis.
    Xu HB; Jiang RH; Xiao HP
    Clin Microbiol Infect; 2012 Nov; 18(11):1104-10. PubMed ID: 22192631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB; Karaoui LR; Mansour H
    Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant tuberculosis: treatment is empirical, for want of robust trials.
    Prescrire Int; 2014 Oct; 23(153):245-6. PubMed ID: 25964976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.